Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bioasis Technologies Inc. V.BTI

Alternate Symbol(s):  BIOAF

Bioasis Technologies Inc. is a multi-asset rare and orphan disease biopharmaceutical company developing clinical stage programs based on epidermal growth factors and the xB3™ platform, a proprietary technology for the delivery of therapeutics across the blood brain barrier and the treatment of CNS disorders in areas of high unmet medical need. The in-house development programs are designed to develop symptomatic and disease-modifying treatments for brain-related diseases and disorders.


TSXV:BTI - Post by User

Comment by JDavenporton Dec 14, 2022 5:17pm
146 Views
Post# 35171909

RE:You KnowWhat Really Hurts?

RE:You KnowWhat Really Hurts?Lot of victims around, beenthere. You're not alone this time.

About my postings, I'm waiting for somebody to make a case for this deal.

RH, maybe.

Cory Wright.

chrispi

This isn't a shot at them. I have no expectations of them showing naivety, or blowing smoke. Is there anything in the deal that signals a little blue sky for Bioasis shareholders, or is it all dark and stormy?

DrDR tried to sell it, did the roadshows, with almost not a word about xB3. It's clear that nobody in the deal wants to tout the potential value of xB3. But for all long term Bioasis shareholders, it's all about getting drugs across the BBB with xB3 and the huge value that is possible with that. 

Is there any conclusion to be drawn other than Bioasis shareholders may have been betrayed by their CEO and BoD?

jd
<< Previous
Bullboard Posts
Next >>